Indiana House backs broader ban on synthetic drugs
The Indiana House has approved a bill that would broaden the state's ban on synthetic drugs to include compounds nicknamed "bath salts" and others that mimic marijuana.
Health Care
Articles
WellPoint earnings fall well short of analysts’ expectations
The Indianapolis-based health insurer reported earnings of $335.3 million, or 96 cents per share, down 39 percent from the same quarter a year ago.
Eli Lilly unit plans to buy feed-enzyme maker
Drugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products that improve poultry, egg and meat production.
Deal with Walgreen perplexes Arcadia’s investors
Something doesn’t add up about Arcadia Resources Inc.’s agreement to sell its pharmacy business for a low price of $2 million, according to many of the Indianapolis company’s investors.
French breast-implant recall could sway U.S. device debate
U.S. medical device makers have spent the last year urging government officials to approve high-risk products faster, like their European counterparts. A scandal over leaking breast implants made in France, however, may make the argument more difficult.
Lilly’s Zyprexa pact with health providers wins approval
Eli Lilly and Co. has won approval of a $4.5 million settlement with five union health funds and an insurer that alleged improper marketing of the company's best-selling medication, Zyprexa, raised their costs.
Rating doctors and other health care providers
A new onslaught of Medicare data might shine more light on providers, but tricky questions abound.
Once-rising star AIT Laboratories now cutting jobs
AIT Laboratories, one of the area’s fastest-growing companies in recent years, confirmed Tuesday that it is eliminating jobs, but would not say how many. The company said it is restructuring.
Drugmaker plans 234 Terre Haute jobs by 2016
A California-based pharmaceutical company says it expects to hire 234 people by 2016 at a new operation on the site of a former Pfizer Inc. drug plant near Terre Haute.
Pressure rises as Lilly tries squeeze play
Indianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire, even as the company needs to spend more money on marketing and research to boost sales of new drugs.
Boston lawsuit claims DES-breast cancer link
Fifty-three women from around the country are suing drug companies, including Eli Lilly and Co., who made and promoted DES for millions of pregnant women from about 1938 to the early 1970s.
Healthx receives $22M capital infusion
Frontier Capital in Charlotte, N.C., provided the funding that will support the continued expansion of Healthx, a local provider of online health care portals.
Lilly challenging Biogen patent in London lawsuit
Eli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system diseases.
WellPoint, other insurers profit from health law they oppose
Insurance companies spent millions of dollars trying to defeat the U.S. health-care overhaul. But profit margins at the companies have widened to levels not seen since before the recession, a Bloomberg Government study shows.
Lilly’s 2012 earnings forecast misses analyst estimates
Indianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast Thursday morning that missed analyst estimates by a wide margin, sending shares down.
Walgreen expects to lose most Express Scripts biz
Drugstore operator Walgreen Co. said Thursday it expects to lose almost 90 percent of prescriptions handled by pharmacy benefits manager Express Scripts Inc. after it leaves Express Scripts' networks on Jan. 1.
Lilly losing dominance in diabetes treatment
Eli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses on other products that have begun to sap the drugmaker’s sales.
Endocyte stays course despite being battered by investors
After spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West Lafayette-based drug developer is in better position than ever.
Q&A
Dr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.
Arcadia agrees to sell DailyMed to Walgreen
It looks like Arcadia Resources Inc.’s DailyMed pharmacy business will live on—but under the wing of Walgreen Co. instead of on its own.